|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NDUFS5 |
Gene summary for NDUFS5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NDUFS5 | Gene ID | 4725 |
| Gene name | NADH:ubiquinone oxidoreductase subunit S5 | |
| Gene Alias | CI-15k | |
| Cytomap | 1p34.3 | |
| Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | O43920 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4725 | NDUFS5 | CA_HPV_1 | Human | Cervix | CC | 1.23e-13 | -4.24e-01 | 0.0264 |
| 4725 | NDUFS5 | CA_HPV_3 | Human | Cervix | CC | 3.17e-04 | -1.15e-02 | 0.0414 |
| 4725 | NDUFS5 | CCI_1 | Human | Cervix | CC | 3.88e-25 | -1.19e+00 | 0.528 |
| 4725 | NDUFS5 | CCI_2 | Human | Cervix | CC | 2.81e-16 | -1.02e+00 | 0.5249 |
| 4725 | NDUFS5 | CCI_3 | Human | Cervix | CC | 5.68e-28 | -1.12e+00 | 0.516 |
| 4725 | NDUFS5 | CCII_1 | Human | Cervix | CC | 6.81e-42 | -1.18e+00 | 0.3249 |
| 4725 | NDUFS5 | sample3 | Human | Cervix | CC | 1.02e-14 | -2.87e-01 | 0.1387 |
| 4725 | NDUFS5 | H2 | Human | Cervix | HSIL_HPV | 4.56e-06 | -3.91e-01 | 0.0632 |
| 4725 | NDUFS5 | L1 | Human | Cervix | CC | 1.14e-11 | -4.65e-01 | 0.0802 |
| 4725 | NDUFS5 | T3 | Human | Cervix | CC | 7.10e-18 | -2.89e-01 | 0.1389 |
| 4725 | NDUFS5 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.66e-23 | 5.59e-01 | 0.0155 |
| 4725 | NDUFS5 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.45e-24 | 7.15e-01 | -0.1808 |
| 4725 | NDUFS5 | HTA11_1938_2000001011 | Human | Colorectum | AD | 7.82e-36 | 1.21e+00 | -0.0811 |
| 4725 | NDUFS5 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.26e-03 | 2.89e-01 | -0.1088 |
| 4725 | NDUFS5 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.69e-38 | 9.00e-01 | -0.1954 |
| 4725 | NDUFS5 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.94e-09 | 1.01e+00 | -0.2602 |
| 4725 | NDUFS5 | HTA11_2112_2000001011 | Human | Colorectum | SER | 7.11e-09 | 1.16e+00 | -0.2196 |
| 4725 | NDUFS5 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.98e-21 | 9.35e-01 | -0.1207 |
| 4725 | NDUFS5 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.49e-25 | 1.09e+00 | -0.1526 |
| 4725 | NDUFS5 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.30e-46 | 1.12e+00 | -0.1464 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004603410 | Cervix | CC | ATP metabolic process | 90/2311 | 277/18723 | 7.90e-19 | 2.36e-15 | 90 |
| GO:000611910 | Cervix | CC | oxidative phosphorylation | 55/2311 | 141/18723 | 7.12e-16 | 1.42e-12 | 55 |
| GO:00090609 | Cervix | CC | aerobic respiration | 60/2311 | 189/18723 | 1.59e-12 | 6.36e-10 | 60 |
| GO:00427739 | Cervix | CC | ATP synthesis coupled electron transport | 38/2311 | 95/18723 | 8.45e-12 | 2.66e-09 | 38 |
| GO:00427759 | Cervix | CC | mitochondrial ATP synthesis coupled electron transport | 38/2311 | 95/18723 | 8.45e-12 | 2.66e-09 | 38 |
| GO:00196469 | Cervix | CC | aerobic electron transport chain | 36/2311 | 87/18723 | 9.15e-12 | 2.74e-09 | 36 |
| GO:00229049 | Cervix | CC | respiratory electron transport chain | 42/2311 | 114/18723 | 1.67e-11 | 4.77e-09 | 42 |
| GO:00453339 | Cervix | CC | cellular respiration | 66/2311 | 230/18723 | 2.07e-11 | 5.39e-09 | 66 |
| GO:00229009 | Cervix | CC | electron transport chain | 53/2311 | 175/18723 | 2.23e-10 | 3.43e-08 | 53 |
| GO:00060919 | Cervix | CC | generation of precursor metabolites and energy | 105/2311 | 490/18723 | 7.40e-09 | 6.61e-07 | 105 |
| GO:00159809 | Cervix | CC | energy derivation by oxidation of organic compounds | 74/2311 | 318/18723 | 3.83e-08 | 2.53e-06 | 74 |
| GO:00061209 | Cervix | CC | mitochondrial electron transport, NADH to ubiquinone | 22/2311 | 51/18723 | 4.01e-08 | 2.54e-06 | 22 |
| GO:00102579 | Cervix | CC | NADH dehydrogenase complex assembly | 22/2311 | 57/18723 | 4.28e-07 | 1.67e-05 | 22 |
| GO:00329819 | Cervix | CC | mitochondrial respiratory chain complex I assembly | 22/2311 | 57/18723 | 4.28e-07 | 1.67e-05 | 22 |
| GO:00331089 | Cervix | CC | mitochondrial respiratory chain complex assembly | 26/2311 | 93/18723 | 3.97e-05 | 6.18e-04 | 26 |
| GO:004603415 | Cervix | HSIL_HPV | ATP metabolic process | 36/737 | 277/18723 | 3.06e-10 | 7.02e-08 | 36 |
| GO:000611914 | Cervix | HSIL_HPV | oxidative phosphorylation | 23/737 | 141/18723 | 6.76e-09 | 8.80e-07 | 23 |
| GO:001964614 | Cervix | HSIL_HPV | aerobic electron transport chain | 15/737 | 87/18723 | 1.38e-06 | 6.26e-05 | 15 |
| GO:000906014 | Cervix | HSIL_HPV | aerobic respiration | 23/737 | 189/18723 | 1.59e-06 | 6.90e-05 | 23 |
| GO:004277314 | Cervix | HSIL_HPV | ATP synthesis coupled electron transport | 15/737 | 95/18723 | 4.31e-06 | 1.70e-04 | 15 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0493219 | Cervix | CC | Non-alcoholic fatty liver disease | 58/1267 | 155/8465 | 3.58e-12 | 1.05e-10 | 6.23e-11 | 58 |
| hsa04714110 | Cervix | CC | Thermogenesis | 76/1267 | 232/8465 | 4.29e-12 | 1.16e-10 | 6.85e-11 | 76 |
| hsa0501419 | Cervix | CC | Amyotrophic lateral sclerosis | 103/1267 | 364/8465 | 1.79e-11 | 4.47e-10 | 2.64e-10 | 103 |
| hsa0472319 | Cervix | CC | Retrograde endocannabinoid signaling | 42/1267 | 148/8465 | 1.79e-05 | 1.42e-04 | 8.40e-05 | 42 |
| hsa0501225 | Cervix | HSIL_HPV | Parkinson disease | 43/459 | 266/8465 | 6.69e-11 | 6.53e-09 | 5.28e-09 | 43 |
| hsa0502024 | Cervix | HSIL_HPV | Prion disease | 40/459 | 273/8465 | 6.26e-09 | 3.67e-07 | 2.97e-07 | 40 |
| hsa0019024 | Cervix | HSIL_HPV | Oxidative phosphorylation | 25/459 | 134/8465 | 4.23e-08 | 1.55e-06 | 1.25e-06 | 25 |
| hsa0541524 | Cervix | HSIL_HPV | Diabetic cardiomyopathy | 30/459 | 203/8465 | 4.38e-07 | 1.07e-05 | 8.64e-06 | 30 |
| hsa0501624 | Cervix | HSIL_HPV | Huntington disease | 38/459 | 306/8465 | 1.21e-06 | 2.54e-05 | 2.05e-05 | 38 |
| hsa0520825 | Cervix | HSIL_HPV | Chemical carcinogenesis - reactive oxygen species | 30/459 | 223/8465 | 3.28e-06 | 5.65e-05 | 4.57e-05 | 30 |
| hsa0502224 | Cervix | HSIL_HPV | Pathways of neurodegeneration - multiple diseases | 46/459 | 476/8465 | 8.10e-05 | 1.08e-03 | 8.72e-04 | 46 |
| hsa0501024 | Cervix | HSIL_HPV | Alzheimer disease | 38/459 | 384/8465 | 2.13e-04 | 2.31e-03 | 1.86e-03 | 38 |
| hsa0501424 | Cervix | HSIL_HPV | Amyotrophic lateral sclerosis | 35/459 | 364/8465 | 6.43e-04 | 5.23e-03 | 4.23e-03 | 35 |
| hsa0471425 | Cervix | HSIL_HPV | Thermogenesis | 25/459 | 232/8465 | 7.63e-04 | 5.88e-03 | 4.76e-03 | 25 |
| hsa0493224 | Cervix | HSIL_HPV | Non-alcoholic fatty liver disease | 18/459 | 155/8465 | 1.77e-03 | 1.24e-02 | 9.99e-03 | 18 |
| hsa0501235 | Cervix | HSIL_HPV | Parkinson disease | 43/459 | 266/8465 | 6.69e-11 | 6.53e-09 | 5.28e-09 | 43 |
| hsa0502034 | Cervix | HSIL_HPV | Prion disease | 40/459 | 273/8465 | 6.26e-09 | 3.67e-07 | 2.97e-07 | 40 |
| hsa0019034 | Cervix | HSIL_HPV | Oxidative phosphorylation | 25/459 | 134/8465 | 4.23e-08 | 1.55e-06 | 1.25e-06 | 25 |
| hsa0541534 | Cervix | HSIL_HPV | Diabetic cardiomyopathy | 30/459 | 203/8465 | 4.38e-07 | 1.07e-05 | 8.64e-06 | 30 |
| hsa0501634 | Cervix | HSIL_HPV | Huntington disease | 38/459 | 306/8465 | 1.21e-06 | 2.54e-05 | 2.05e-05 | 38 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NDUFS5 | SNV | Missense_Mutation | rs368988409 | c.206G>A | p.Arg69Gln | p.R69Q | O43920 | protein_coding | tolerated(0.06) | benign(0.116) | TCGA-AC-A7VB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NDUFS5 | SNV | Missense_Mutation | novel | c.163N>A | p.Glu55Lys | p.E55K | O43920 | protein_coding | deleterious(0) | possibly_damaging(0.896) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| NDUFS5 | SNV | Missense_Mutation | novel | c.137N>A | p.Gly46Glu | p.G46E | O43920 | protein_coding | tolerated(0.06) | probably_damaging(1) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
| NDUFS5 | SNV | Missense_Mutation | c.94N>G | p.Arg32Gly | p.R32G | O43920 | protein_coding | deleterious(0.03) | possibly_damaging(0.591) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| NDUFS5 | SNV | Missense_Mutation | c.189N>A | p.Phe63Leu | p.F63L | O43920 | protein_coding | tolerated(0.16) | benign(0.04) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| NDUFS5 | SNV | Missense_Mutation | c.184G>T | p.Asp62Tyr | p.D62Y | O43920 | protein_coding | deleterious(0.05) | benign(0.046) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| NDUFS5 | SNV | Missense_Mutation | c.223C>T | p.Arg75Cys | p.R75C | O43920 | protein_coding | tolerated(0.07) | benign(0.015) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| NDUFS5 | SNV | Missense_Mutation | rs375631916 | c.205N>T | p.Arg69Trp | p.R69W | O43920 | protein_coding | tolerated(0.11) | benign(0.027) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| NDUFS5 | SNV | Missense_Mutation | rs541997196 | c.190N>A | p.Val64Ile | p.V64I | O43920 | protein_coding | tolerated(0.8) | benign(0) | TCGA-EY-A549-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NDUFS5 | SNV | Missense_Mutation | c.99N>G | p.Cys33Trp | p.C33W | O43920 | protein_coding | deleterious(0) | benign(0.054) | TCGA-95-7567-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4725 | NDUFS5 | ENZYME | inhibitor | CHEMBL3545135 | NV-128 | |
| 4725 | NDUFS5 | ENZYME | inhibitor | CHEMBL3545320 | ME-344 | |
| 4725 | NDUFS5 | ENZYME | inhibitor | CHEMBL1703 | METFORMIN HYDROCHLORIDE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |